Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 628Stomach Neoplasms 76Neoplasm Metastasis 59Neoplasms 39HER2-positive Breast Cancer 33Breast Neoplasms, Male 30Colorectal Neoplasms 28Brain Neoplasms 25Carcinoma, Non-Small-Cell Lung 21Inflammatory Breast Neoplasms 20Esophageal Neoplasms 20Pancreatic Neoplasms 13Triple Negative Breast Neoplasms 12Lung Neoplasms 11Endometrial Neoplasms 11Ovarian Neoplasms 10Colonic Neoplasms 10Urinary Bladder Neoplasms 9Rectal Neoplasms 9Prostatic Neoplasms 9Cardiotoxicity 8Adenocarcinoma 8Salivary Gland Neoplasms 7Gallbladder Neoplasms 7Breast Diseases 7Biliary Tract Neoplasms 7Adenocarcinoma Of Esophagus 7Uterine Cervical Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Sarcoma 6

Interventions

Fulvestrant 6Letrozole 4Capecitabine 4exemestane 3dalpiciclib 3Trastuzumab 3Docetaxel 3Anastrozole 3ribociclib 2palbociclib 2fluzoparib 2apatinib 2Irinotecan 2Gemcitabine 2tusamitamab ravtansine 1trastuzumab deruxtecan 1sacituzumab govitecan 1pyrotinib 1pegfilgrastim 1patritumab deruxtecan 1olaparib 1nirogacestat 1margetuximab 1irinotecan sucrosofate 1abemaciclib 1Zoledronic Acid 1Vinorelbine 1Tamoxifen 1Rogaratinib 1Patient Reported Outcome Measures 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Breast Cancer Metastatic × Trastuzumab × Clear all
NCT04262804 2023-08-22

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Zai Lab (Hong Kong), Ltd.

Phase 2 Unknown
123 enrolled
Breast

Breast Cancer Metastatic

NCT05301010 2023-02-27

Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients

Nanogen Pharmaceutical Biotechnology Joint Stock Company

Phase 3 Completed
128 enrolled
Breast

Breast Cancer Metastatic

NCT05301530 2022-03-29

Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.

Nanogen Pharmaceutical Biotechnology Joint Stock Company

Phase 1 Completed
50 enrolled
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡